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OBJECTIVES: Nonalcoholic fatty pancreas disease (NAFPD) is characterized by excessive fat deposition in the
pancreas in the absence of alcohol consumption. In this study, we aimed to detect a possible relationship
between adipose tissue accumulation, prediabetes and diabetes.
METHODS: This cross-sectional and retrospective study included 110 patients. Three groups were classified as
controls, patients with prediabetes and patients with type 2 diabetes. The abdominal computed tomography
(CT) attenuation measurement results of the pancreas were evaluated independently by two experienced
radiologists. CT measurements and biochemical parameters were compared between study groups. The
relationship between continuous variables was assessed by using one-way ANOVA. To determine the changes in
the dependent variable for the effects on study groups, the independent variable was adjusted using ANCOVA.
A p-value less than 0.05 was considered statistically significant.
RESULTS: The presence of prediabetes and type 2 diabetes was correlated with a decrease in the mean
Hounsfield Unit (HU) value of the pancreas (p=0.002). Age was determined to be an independent risk factor
and was correlated with NAFPD (p=0.0001). When compared to the controls (p=0.041), 71% of patients
with prediabetes and 67% of patients with type 2 diabetes were observed to have an increased incidence of
NAFPD. Decreased serum amylase was found to be correlated with the mean HU value of the pancreas
(p=0.043).
CONCLUSION: NAFPD was independently correlated with both prediabetes and type 2 diabetes adjusted for age
(p=0.0001) in this study. Additionally, age was determined to be an independent risk factor and was correlated
with NAFPD.
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’ INTRODUCTION
Obesity and diabetes are major health problems that lead
to infiltration of visceral adipose tissue in addition to athero-
sclerotic cardiovascular diseases (1). Visceral fat deposition
develops in organs such as the liver, pancreas and skeletal
muscle as a result of ectopic adiposity (2). Nonalcoholic fatty
pancreas disease (NAFPD) is closely associated with nona-
lcoholic fatty liver disease (NAFLD), diabetes, obesity and meta-
bolic syndrome (3). NAFPD is excessive lipid deposition in the
pancreas without alcohol consumption (4). Both low-grade
inflammation and insulin resistance play an important role in
the development of NAFPD. Sustained lipid accumulation in
adipocytes causes elevated secretion of fat-derived proin-
flammatory molecules such as interleukin-6, tumor necrosis
factor-a, and monocyte chemotactic protein-1 within pan-
creatic islets (5). Fatty infiltration related to inflammation can
cause b-cell apoptosis, endocrine dysfunction and fibrosis of
the pancreas. However, diabetes is known to have an impor-
tant role in the progression of NAFPD (6-8), and there is
limited data on the relationship between NAFPD and pre-
diabetes, which is a metabolic parameter associated with
insulin resistance. Prediabetes may promote NAFPD and
pancreatic dysfunction. The aim of this study was to deter-
mine the relationships between NAFPD and both prediabetes
and type 2 diabetes.
’ METHODS
Study participants
This retrospective study was conducted from January 2016
to January 2017 in Haseki Training and Research Hospital,DOI: 10.6061/clinics/2019/e1337
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University of Health Sciences in I˙stanbul. Haseki Training
and Research Hospital’s local ethics committee approved the
study design (Reference No: 03R/2018, Date: January 23rd,
2018). The database information was anonymized and app-
roved by the ethics committee with no need for consent. Data
for the study were derived from the electronic management
system of the hospital. Patients selected for evaluation in this
study had been admitted to our internal medicine outpatient
clinic with complaints (such as abdominal pain, chronic
dyspepsia, chronic constipation, etc.) and underwent an
abdominal computed tomography (CT) scan during the
differential diagnosis investigation as part of the clinician’s
evaluation. Patients with acute abdominal syndrome, viral
hepatitis, pancreatitis, hepatic cirrhosis, chronic renal dis-
ease, sepsis, chronic heart failure, malignancy, alcohol con-
sumption, neurological and psychiatric disease were excluded
from the study. In this study, a total of 110 patients were found
to be eligible. Biochemical parameters [serum glycosylated
hemoglobin (HbA1c), fasting blood glucose (FBG), creatinine,
urea, hepatic and biliary enzymes, amylase, lipase, lipid pro-
files, albumin and c-reactive protein (CRP) levels] of the study
patients were evaluated. Biochemical analysis was performed
with an Abbott Architect Analyzer System (IL, USA). Three
groups were included as nondiabetic controls (n=39), patients
with prediabetes (n=43) and patients with type 2 diabetes
(n=28). The study groups were classified according to the
medical history of the participants, taking into account the
hospital database records of patients with diabetes and pre-
diabetes who were previously identified and receiving treat-
ment. Prediabetes and type 2 diabetes mellitus were described
according to the Standards of Medical Care in Diabetes 2018
criteria by the American Diabetes Association (9). Prediabetes
was defined as patients with FBG between 5.6-6.9 mmol/L
and/or HbA1c 39-47 mmol/mol. Diabetes mellitus was defined
as patients who had FBG X7 mmol/L, 2 hours postprandial
glucose X11.1 mmol/L and/or HbA1c X48 mmol/mol. The
biochemical and CT results were compared among the study
groups.
Radiological evaluation
Abdominal CT scans were performed with a 64-detector
Philips Brilliance CT device (Philips Medical Systems,
Cleveland, Ohio). All the images were acquired according
to a routine intravenous contrast-enhanced abdominal CT
protocol (upper abdominal CT without axial contrast and
whole abdominal CT taken in portal venous phase at 60 s).
The shooting parameters were as follows: tube current
20 mAs; tube voltage, 120 kVp; pitch, 0.671; collimation,
64x0.625 mm; rotation time, 0.5s; cross-sectional thickness,
5 mm; and reconstruction range, 4 mm. Images were taken
from pre-contrast axial sections using INFINITT PACS
version 3.0.11.4 (INFINITT Healthcare Co. Ltd., Korea) by
two expert radiologists with 5 years of experience. Radi-
ologists were blinded to the patients’ clinical data. Attenua-
tion values of the liver, spleen and pancreas were measured
and expressed as Hounsfield Units (HUs). The attenuation
measurements were performed using a 0.5 cm2 elliptical
region of interest (ROI). Liver attenuation was determined as
the average of the measurements made from the right, left
and caudate lobes, and spleen attenuation was determined
by taking the average of three measurements made from the
lower, middle and upper parts of the spleen. During the
assessment, care was taken not to measure formations that
could affect the measurement, such as mass, cysts and
calcification of the ROI. Attenuation measurements of the
caput, corpus and cauda pancreas were separately recorded
and evaluated independently by two experienced radiolo-
gists. The arithmetic mean of these three measurements was
considered the mean attenuation HU value of the pancreas.
Pancreatic vascular structures were not included in pancrea-
tic attenuation measurements. CT-estimated NAFPD was
defined as the difference in pancreas-spleen attenuation in
negative HU value (10-13). The median was calculated
according to the mean HU value of the pancreas of control
patients. A cutoff value was determined (-4.00 HU, min: -17.00
and max: 21.00) to diagnose the CT-estimated incidence of
NAFPD in patients with prediabetes and type 2 diabetes.
Statistical analysis
Data were expressed as the mean ± standard deviation.
SPSS 16.0 for Windows was used to perform statistical analy-
sis. The distributions of variables were assessed by using the
Kolmogorov-Smirnov Z test. T tests were used to analyze
normally distributed variables, and the Mann-Whitney U
test was used to analyze nonnormally distributed variables.
The relationship between continuous variables was detected
by using one-way ANOVA, and subgroup analysis was
interpreted according to Bonferroni correction in parametric
tests. The chi square test was used to evaluate categorical
variables. Pearson and Spearman correlation analyses were
performed to analyze the correlation between variables.
When investigating changes in the dependent variable for
the effects on study groups, the independent variable was
adjusted using analysis of covariance (ANCOVA). A p-value
less than 0.05 was considered statistically significant.
’ RESULTS
A total of 991 patients who were admitted to the internal
medicine clinic and underwent abdominal CT for any
medical purpose as a further examination were investigated
via the hospital’s medical database. Exclusion criteria were
set to eliminate many diseases that may affect biochemical
parameters and CT scan measurements of the pancreas and
liver. Acute abdominal syndrome, viral hepatitis, pancreati-
tis, hepatic cirrhosis, chronic renal disease, sepsis, chronic
heart failure, malignancy, alcohol consumption, and neuro-
psychiatric diseases were reasons for exclusion in this study.
Following a detailed medical database investigation, 110
patients did not meet the exclusion criteria and were selected
for the study. The characteristics and biochemical parameters
of the study groups are shown in Table 1. The mean age of
the control group was 55.28±14.19; patients with predia-
betes, 63.88±14.97; and patients with type 2 diabetes,
65.18±11.02; the difference was statistically significant
(po0.005). The mean FBG and HbA1c levels were
5.05±0.36 mmol/L and 36.0±2.1 mmol/mol in controls,
5.91±0.80 mmol/L and 40.8±2.0 mmol/mol in patients
with prediabetes and 7.80±3.67 mmol/L and 55.1±8.6
mmol/mol in patients with type 2 diabetes, respectively
(p=0.0001 and 0.0001). The mean high-density lipoprotein
(HDL) cholesterol was 1.30±0.30 mmol/L in controls,
1.19±0.29 mmol/L in patients with prediabetes and
1.10±0.36 mmol/L in patients with type 2 diabetes
(p=0.035). Other biochemical parameters were not signifi-
cantly different between groups. CT attenuation measure-
ments of the liver, pancreas and spleen of the study patients
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are shown in Table 2. A decrease in pancreatic attenuation
and a negative HU value between the pancreas and spleen
were diagnostic for NAFPD. Caput, corpus, cauda and mean
HU values of the pancreas were significantly decreased in
patients with prediabetes and type 2 diabetes. Mean HU
attenuation differences between the parts of the pancreas and
spleen were statistically significant between groups. A
significant increase in pancreatic fat accumulation was found
in both patients with prediabetes and those with type 2
diabetes compared to controls (p=0.041). Caput, corpus, cauda
and mean HU values of the pancreas were observed to
correlate with age, FBG and HbA1c, as shown in Table 3.
Serum CRP levels were significantly elevated in patients with
prediabetes and those with type 2 diabetes compared with
controls (p=0.004). On the other hand, CRP levels were also
categorized according to our laboratory’s cutoff value (47.62
nmol/L) because of the wide range of distribution. Serum
amylase levels correlated with corpus, cauda and mean HU
value of the pancreas. Mean HDL cholesterol and triglyceride
levels were found to correlate with only the attenuation HU of
liver. ANCOVA was performed to reveal the effect of type 2
diabetes and prediabetes on the mean HU value of the
pancreas adjusted for age. The presence of type 2 diabetes and
prediabetes correlated with a decrease in the mean HU value
of the pancreas (p=0.002), as shown in Table 4. A contrast
hypothesis (K Matrix) was applied to compare the relation-
ship of the mean HU values of the pancreas between patients
with prediabetes versus controls (Level 2 vs. Level 1) and
patients with type 2 diabetes versus controls (Level 3 vs. Level
1). Contrast results were statistically significant (Table 5);
p=0.015, 95% CI:-1.117 and -10.483 for Level 2 vs. Level 1, and
p=0.001, 95% CI:-3.987 and -14.431 for Level 3 vs. Level 1.
’ DISCUSSION
Prediabetes and diabetes are associated with visceral
adipose tissue accumulation, especially in the pancreas and
liver, and has important clinical consequences in addition to
atherosclerosis. NAFPD varies from simple fat storage and
inflammation to the development of pancreatic fibrosis.
NAFPD is one of the manifestations of type 2 diabetes and
metabolic syndrome (14). We found that NAFPD indepen-
dently correlated with both prediabetes and type 2 diabetes
adjusted for age and that aging is an important risk factor for
fatty pancreas. Moreover, we observed that NAFPD is wide-
spread in all parts of the pancreas, not only in specific regions.
Table 1 - General characteristics and biochemical parameters of the study groups.
Parameters (laboratory ranges) Controls (n: 39) Patients with prediabetes (n: 43) Patients with type 2 diabetes (n: 28) p-value
Age 55.28±14.19 63.88±14.97 65.18±11.02 0.005
FBG (3.9-6.1 mmol/L) 5.05±0.36 5.91±0.80 7.80±3.67 0.0001
HbA1c (20-48 mmol/mol) 36.0±2.1 40.8±2.0 55.1±8.6 0.0001
ALT (0.17-0.68 mkat/L) 0.39±0.23 0.60±1.16 0.37±0.17 0.32
AST (0.17-0.58 mkat/L) 0.39±0.10 0.55±0.84 0.35±0.11 0.23
Amylase (0.46-1.67 mkat/L) 1.44±0.84 1.28±0.40 1.32±0.80 0.56
Lipase (0.08-1.12 mkat/L) 0.57±0.70 0.41±0.29 0.74±0.99 0.18
GGT (0.03-0.62 mkat/L) 0.45±0.24 1.12±3.01 0.55±0.35 0.24
ALP (0.5-2.0 mkat/L) 1.34±0.33 1.50±0.78 1.61±0.67 0.20
Total cholesterol (o5.18 mmol/L) 5.46±1.19 5.10±1.23 4.79±1.08 0.076
HDL cholesterol (41.03 mmol/L) 1.30±0.30 1.19±0.29 1.10±0.36 0.035
LDL cholesterol (o4.14 mmol/L) 3.44±0.95 3.10±1.05 2.91±0.97 0.08
Triglyceride (o1.69 mmol/L) 1.56±0.71 1.85±0.99 1.71±0.80 0.32
LDH (1.7-4.12 mkat/L) 3.10±0.49 3.14±0.57 3.04±0.82 0.79
Albumin (35-50 g/L) 43.30±3.60 42.20±3.20 41.00±4.70 0.06
CRP (o47.62 nmol/L) 55.14±99.53 110.76±197.43 237.72±337.53 0.004
Hypertensive patients (n, %) 10/39, 25% 12/43, 27% 9/28, 32% 0.56
(FBG: fasting blood glucose, HbA1c: glycosylated hemoglobin, ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma glutamyl
transferase, ALP: alkaline phosphatase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, LDH: lactate dehydrogenase, CRP: c-reactive protein)
(statistically significant p-values were expressed in bold and italic)
Table 2 - A comparison of CT attenuation measurements of the liver, parts of the pancreas and spleen between the patient groups.
Controls (n: 39) Patients with prediabetes (n: 43) Patients with type 2 diabetes (n: 28) p-value
Liver (HU) 55.37±8.93 53.15±7.63 50.21±10.75 0.072
Caput Pancreas (HU) 44.03±5.96 35.72±12.82 31.96±14.50 0.0001
Corpus Pancreas (HU) 43.59±7.17 35.00±12.29 30.61±14.61 0.0001
Cauda Pancreas (HU) 41.69±7.68 34.51±12.28 31.50±13.28 0.001
Mean HU of Pancreas 43.09±6.19 35.05±11.85 31.34±13.72 0.0001
Spleen (HU) 48.69±4.50 47.05±5.57 45.39±6.22 0.05
Caput P-S value (HU) -4.66±7.19 -11.32±12.01 -13.42±16.94 0.008
Corpus P-S value (HU) -5.10±8.21 -12.04±12.47 -14.78±16.78 0.005
Cauda P-S value (HU) -7.00±8.03 -12.53±12.15 -13.89±15.05 0.035
Mean HU of P-S value -5.60±7.14 -11.98±11.58 -14.04±15.91 0.008
NAFPD (n, %) 18/39, 46% 31/43, 72% 19/28, 67% 0.041
(HU: Hounsfield unit, P-S value: difference between HU values of part of pancreas and spleen, NAFPD: nonalcoholic fatty pancreas disease, n: number of
patients)
(statistically significant p-values were expressed in bold and italic)
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ANCOVA is a useful statistical technique for eliminating the
effect of a different numerical variable (such as age) during
the comparison of the means of a variable in two or more
groups. As a result of ANCOVA, prediabetes and diabetes
were found to be independently related to the development
of NAFPD. Contrast results revealed that the presence of
prediabetes and diabetes were consistent with the increase in
pancreatic fat content. Furthermore, prediabetes and diabetes
were found to have an independent role in the progression of
visceral fat accumulation and NAFPD (14). Ou et al. also
Table 3 - Correlations between age, biochemical parameters and CT-estimated HU values of liver and pancreas.
Age FBG HbA1c Amylase Triglyceride HDL
Liver (HU) r 0.039 -0.221 -0.28 -0.10 -0.278 0.201
p 0.682 0.02 0.004 0.297 0.004 0.037
Caput Pancreas (HU) r -0.363 -0.295 -0.464 0.167 -0.02 0.121
p 0.0001 0.002 0.0001 0.082 0.839 0.212
Corpus Pancreas (HU) r -0.390 -0.304 -0.498 0.189 -0.049 0.125
p 0.0001 0.001 0.0001 0.048 0.612 0.198
Cauda Pancreas (HU) r -0.420 -0.274 -0.464 0.20 -0.035 0.068
p 0.0001 0.004 0.0001 0.036 0.72 0.486
Mean HU of Pancreas r -0.408 -0.304 -0,496 0.194 -0.036 0.11
p 0.0001 0.001 0.0001 0.043 0.711 0.259
Caput P-S value (HU) r -0.341 -0.156 -0.347 0.125 0.052 0.041
p 0.0001 0.103 0.0001 0.195 0.593 0.672
Corpus P-S value (HU) r -0.361 -0.164 -0.375 0.144 0.021 0.045
p 0.0001 0.087 0.0001 0.133 0.827 0.642
Cauda P-S value (HU) r -0.398 -0.131 -0.345 0.156 0.04 -0.015
p 0.0001 0.174 0.0001 0.103 0.679 0.881
Mean P-S value (HU) r -0.382 -0.157 -0.37 0.148 0.039 0.026
p 0.0001 0.102 0.0001 0.124 0.686 0.793
(HU: Hounsfield unit, P-S value: difference between HU values of part of pancreas and spleen, FBG: fasting blood glucose, HbaA1c: glycosylated
hemoglobin, HDL: high-density lipoprotein)
(statistically significant p-values were expressed in bold and italic)
Table 4 - ANCOVA between-subjects effects. The dependent variable is the mean HU value of the pancreas adjusted for age.
Source Type III Sum of Squares df Mean Square F p-value
Corrected Model 3838.799a 3 1279.600 12.204 0.0001
Intercept 13996.312 1 13996.312 133.492 0.0001
Age 1335.012 1 1335.012 12.733 0.001
Study Groups 1353.861 2 676.930 6.456 0.002
Error 11113.854 106 104.848
Total 165224.621 110
Corrected Total 14952.653 109
aR Squared = 0.257 (Adjusted R Squared = 0.236)
(HU: Hounsfield Unit, statistically significant p-values were expressed in bold and italic)
Table 5 - Contrast hypothesis results between study groups as patients with prediabetes vs. controls (Level 2 vs. Level 1) and patients
with type 2 diabetes vs. controls (Level 3 vs. Level 1).




Mean HU of Pancreas
Level 2 vs. Level 1 Contrast Estimate -5.830
Hypothesized Value 0
Difference (Estimate - Hypothesized) -5.830
Standard Error 2.347
p-value 0.015
95% Confidence Interval for Difference Lower Bound -10.483
Upper Bound -1.177
Level 3 vs. Level 1 Contrast Estimate -9.209
Hypothesized Value 0
Difference (Estimate - Hypothesized) -9.209
Standard Error 2.634
p-value 0.001
95% Confidence Interval for Difference Lower Bound -14.431
Upper Bound -3.987
aReference category = 1
(HU: Hounsfield Unit, statistically significant p-values were expressed in bold and italic)
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indicated that NAFPD was associated with insulin resis-
tance, obesity, prediabetes, metabolic syndrome and diabetes
(15-19). Steatosis of the pancreas with triglyceride accumula-
tion can lead to a decline in b-cell mass and function, and
potentially lead to the development of diabetes (20). More-
over, NAFPD may develop with aging as well as with
diabetes mellitus, and age was found to be an independent
risk factor and was correlated with NAFPD (p=0.0001).
However, 46% of control patients were diagnosed with
NAFPD according to our study, although the incidence of
NAFPD was significantly higher in patients with diabetes
and prediabetes than in controls. Weng et al. repor-
ted that the occurrence of NAFPD increases independently
with age, obesity and diabetes (21). Advanced age is asso-
ciated with pancreatic fat deposition and plays an important
role in pancreatic atrophy and fibrosis (22,23). On the other
hand, the detection of NAFPD in younger control patients
may indicate that NAFPD begins to develop at an earlier age.
In this study, NAFPD incidence was observed in 71% of
patients with prediabetes and 67% of patients with type 2
diabetes, which was significantly higher than in the controls.
Furthermore, NAFPD was found to correlate with FBG and
HbA1c levels in our study. Consistent with our findings, Wu
et al. suggested that metabolic parameters such as abdominal
obesity, FBG and HbA1c were strongly associated with fatty
pancreas (24). CRP is an important marker of inflammation.
In our study, the rates of high CRP levels were 10/39 (25.6%)
in controls, 15/43 (34.3%) in patients with prediabetes and
18/28 (64.3%) in patients with type 2 diabetes. Categorized
CRP levels were elevated in patients with type 2 diabetes
and prediabetes compared with controls. Moreover, CRP
levels were higher in patients with prediabetes and type 2
diabetes than in controls in our study, suggesting a relation-
ship between inflammation and NAFPD.
To accurately identify NAFPD, CT is an approved method
for evaluating pancreatic fat accumulation with or without
contrast and is easily applicable. The density of pancreatic
steatosis was similar to the density of adipose tissue on CT
scan using HU (24). Although there was a decrease in the
mean HU value of the liver, it was not found to be signi-
ficant. van Geenen et al. reported that insulin resistance and
obesity play an important role in steatosis of the liver and
pancreas and adipocyte infiltration. NAFPD and NAFLD are
both a result of insulin resistance (25). NAFPD is a predictor
of NAFLD and is related to hepatic steatosis rather than total
body fat. Central obesity is closely associated with fatty liver
and pancreas in patients with type 2 diabetes and pre-
diabetes (26). Lee et al. suggested a possible relationship
between NAFPD and NAFLD (27). Notably, NAFLD is asso-
ciated with metabolic syndrome and clinical consequences
(28). Moreover, fatty liver was correlated with increased FBG,
triglyceride and decreased HDL in this study. The total
cholesterol level was higher in controls than in patients with
prediabetes and type 2 diabetes, although the difference was
not statistically significant. This finding may be a result of
the patients with type 2 diabetes and prediabetes paying
attention to their diet. Consistent with this finding, LDL cho-
lesterol levels were decreased in patients with diabetes
compared with participants in the other groups, although the
difference was not statistically significant. The prevalence of
impaired glucose tolerance and diabetes is elevated in
NAFLD patients (29,30).
The mean HU values of the pancreas were significantly
correlated with a decrease in serum amylase levels. In other
words, fat accumulation in the pancreas was correlated with
low serum amylase levels. Amylase is an indicator of the
exocrine function of the pancreas. Increased triglyceride
content of pancreatic tissue enhances pancreatic expression
of a fibrogenic marker (TGF-b) and collagen production (31).
NAFPD is associated with a decrease in both endocrine and
exocrine functions of the pancreas as a result of inflammation
and fibrosis (32,33). Therefore, the correlation between a
decreased amylase level and mean pancreas HU value may
be considered a result of the onset of an insufficiency in
pancreatic exocrine functions in our study.
Notably, this study has some limitations. First, this cross-
sectional retrospective study was based only on CT scan
measurements of the pancreas and liver. Medical records and
CT results were examined electronically on the computer.
Radiological methods other than CT may be used to analyze
NAFPD as an external validation. However, anthropometric
measurements of all patients could not be obtained, and
serum insulin levels were not analyzed for all study patients.
Therefore, insulin resistance values were not provided from
the medical records. Insulin resistance and anthropometric
measurements are important parameters for identifying the
presence of metabolic syndrome. Although the results were
age adjusted, the relationship between NAFPD and meta-
bolic parameters could not be evaluated because of the study
design. The results of this study will provide ideas for new
research, and further studies are needed with a larger
number of patients.
’ CONCLUSION
In conclusion, NAFPD was independently correlated
with both prediabetes and type 2 diabetes adjusted for age
(p=0.0001) in this study. Additionally, age was an indepen-
dent risk factor and correlated with NAFPD. Further studies
are needed to investigate the relationship between anthro-
pometric measurements and NAFPD.
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